1-20 of 33
Jon Ukropec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis

Savreet Bains Chawla, Shibing Yang, Jing He, Monika Jun, Nicole Heaps, Anthony Wang, Junhua Yu, Chenxue Liang, Allison Keshishian, Jon Ukropec
Journal: Blood
Blood (2023) 142 (Supplement 1): 5158.
https://doi.org/10.1182/blood-2023-181854
Published: 2023
Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Clinical Trials & Observations
Michele Cavo, Jesus San-Miguel, Saad Z. Usmani, Katja Weisel, Meletios A. Dimopoulos, Hervé Avet-Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vania Hungria, Philippe Moreau, Maria-Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Facon, Shaji Kumar, Niels W. C. J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil Munshi
Journal: Blood
Blood (2022) 139 (6): 835–844.
https://doi.org/10.1182/blood.2021011101
Published: 2022
Includes: Supplemental data
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

Niels W. C. J. van de Donk, Sonja Zweegman, MDPhD, Jesus F. San-Miguel, MD PhD, Meletios A Dimopoulos, Michele Cavo, Kenshi Suzuki, MD PhD, Cyrille Touzeau, Saad Z. Usmani, MDMBBS,MBA, Aurore Perrot, Huiling Pei, PhD, Anupa Kudva, MD, Rian Van Rampelbergh, Jon Ukropec, PhD, Kevin Leary, Robin Carson, MD BA, Ming Qi, MD PhD, Ajai Chari
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-134923
Published: 2020
Journal Articles

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Paula Rodriguez-Otero, Mario Boccadoro, Roman Hajek, MD, Tomoaki Fujisaki, MD, Jae Hoon Lee, MD PhD, Joaquin Martinez-Lopez, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ganna Usenko, MD, Anna Marina Liberati, MD, Mihaela Lazaroiu, MD, Dariusz Woszczyk, MDPhD, Hiroyuki Takamatsu, MDPhD, Joanna Romejko-Jarosinska, Stefan Tobias Knop, Astrid Pavlovsky, MD, Cecily Forsyth, FRACP, FRCPA, MBBS, Takayuki Ishikawa, MD PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Robin Carson, MD BA, Meletios A Dimopoulos
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-136145
Published: 2020
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Peter M. Voorhees, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J. Costa, MD PhD, Yana Lutska, PharmD, Padma Bobba, Daniela Hoehn, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–49.
https://doi.org/10.1182/blood-2020-137105
Published: 2020
Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, MD, Thierry Facon, MD, Saad Z. Usmani, MDMBBS,MBA, Torben Plesner, MD DSc, Robert Z. Orlowski, MDPhD, Cyrille Touzeau, Supratik Basu, Nizar J. Bahlis, MD, Hartmut Goldschmidt, MD, Michael E. O'Dwyer, MD, Christopher P. Venner, MD, Katja Weisel, MD, Cyrille Hulin, MD, Lionel Karlin, MD, Meir Preis, MD PhD, Annemiek Broyl, MD PhD, William Renwick, Markus Hansson, MD, Maria Krevvata, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–26.
https://doi.org/10.1182/blood-2020-134847
Published: 2020
Journal Articles

Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD PhD, Herve Avet-Loiseau, Bruno Paiva, PhD, Shaji K. Kumar, MD, Meletios A. Dimopoulos, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Cyrille Touzeau, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MDMBBS,MBA, Gordon Cook, MD, Michele Cavo, Hang Quach, MDFRACP,FRCPA,MBBS, Jon Ukropec, PhD, Priya Ramaswami, Huiling Pei, PhD, Steven Sun, Jianping Wang, Maria Krevvata, PhD, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, MD, Rachel Kobos, MD, Ming Qi, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134928
Published: 2020
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Jonathan L. Kaufman, MD, Jacob P. Laubach, Douglas Sborov, MD MS, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, Jr., MD PhD, Nitya Nathwani, MD, Nina Shah, MD, Yvonne A. Efebera, MD MPH, Sara A. Holstein, MDPhD, Caitlin Costello, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD MSCI, Robert Z. Orlowski, MDPhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, Yana Lutska, PharmD, Padma Bobba, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD, Peter M. Voorhees
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-137109
Published: 2020
Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Mario Boccadoro, Sosana Delimpasi, MD, Meral Beksac, MD, Eirini Katodritou, MD, Philippe Moreau, MD, Luca Baldini, MD PhD, Argiris Symeonidis, MD PhD, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, MD PhD, Hermann Einsele, MD, Ioannis Orfanidis, Tahamtan Ahmadi, MD PhD, Jon Ukropec, PhD, Tobias Kampfenkel, MD, Jordan Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, MD PhD, Robin Carson, MD BA, Pieter Sonneveld, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135874
Published: 2020
Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Clinical Trials & Observations
Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson
Journal: Blood
Blood (2020) 136 (8): 936–945.
https://doi.org/10.1182/blood.2020005288
Published: 2020
Includes: Supplemental data
Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, MD PhD, Nitya Nathwani, MD, Nina D. Shah, MD, Yvonne A. Efebera, MD MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD, Robert Z. Orlowski, MD PhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 691.
https://doi.org/10.1182/blood-2019-123465
Published: 2019
Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1866.
https://doi.org/10.1182/blood-2019-123483
Published: 2019
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Nizar Bahlis, MD, Thierry Facon, MD, Saad Z. Usmani, MD, Shaji K. Kumar, MD, Torben Plesner, MD DSc, Robert Z. Orlowski, MD, PhD, Cyrille Touzeau, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Hareth Nahi, MD PhD, Cyrille Hulin, MD, Hang Quach, MBBS, FRACP, FRCPA, MD, Hartmut Goldschmidt, Michael E O'Dwyer, MD, Christopher P Venner, MD, Katja C. Weisel, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jianping Wang, Rian Van Rampelbergh, Jon Ukropec, PhD, Clarissa M. Uhlar, Rachel Kobos, MD, Aurore Perrot
Journal: Blood
Blood (2019) 134 (Supplement_1): 1875.
https://doi.org/10.1182/blood-2019-123426
Published: 2019
Journal Articles

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Sagar Lonial, Joaquin Martinez-Lopez, MD PhD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD, Albert Oriol, Paula Rodriguez Otero, Luis Pineiro, Andrzej Jakubowiak, MD PhD, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, PhD, Martin Shreeve, Ming Qi, MD PhD, Philippe Moreau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1876.
https://doi.org/10.1182/blood-2019-123539
Published: 2019
Journal Articles

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Nina D. Shah, MD, Yana Lutska, PharmD, Huiling Pei, PhD, Ming Qi, MD PhD, Maria Krevvata, PhD, Colleen Kane, PhD VMD, Jon Ukropec, PhD, Thomas S. Lin, MD PhD, Shalaka Hampras, MBBS, PhD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 1829.
https://doi.org/10.1182/blood-2019-122471
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019
Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 863.
https://doi.org/10.1182/blood-2019-122497
Published: 2019
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3192.
https://doi.org/10.1182/blood-2019-123527
Published: 2019